FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis
Hepatitis E virus (HEV) infection is the leading cause of acute hepatitis worldwide and can develop into chronic infection in immunocompromised patients, promoting the development of effective antiviral therapies. In this study, we performed a screening of a library containing over 1000 FDA-approved drugs. We have identified deptropine, a classical histamine H1 receptor antagonist used to treat asthmatic symptoms, as a potent inhibitor of HEV replication. The anti-HEV activity of deptropine appears dispensable of the histamine pathway, but requires the inhibition on nuclear factor-κB (NF-κB) activity. This further activates caspase mediated by receptor-interacting protein kinase 1 (RIPK1) to restrict HEV replication. Given deptropine being widely used in the clinic, our results warrant further evaluation of its anti-HEV efficacy in future clinical studies. Importantly, the discovery that NF-κB-RIPK1-caspase pathway interferes with HEV infection reveals new insight of HEV-host interactions.
|Keywords||Caspase, Deptropine, HEV, NF-κB signaling, RIPK1|
|Persistent URL||dx.doi.org/10.1016/j.antiviral.2019.104588, hdl.handle.net/1765/119157|
Qu, C, Li, Y. (Yang), Li, Y. (Yunlong), Yu, P. (Peifa), Li, P. (Pengfei), Donkers, J.M. (Joanne M.), … Pan, Q. (2019). FDA-drug screening identifies deptropine inhibiting hepatitis E virus involving the NF-κB-RIPK1-caspase axis. Antiviral Research, 170. doi:10.1016/j.antiviral.2019.104588